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NADPH oxidases constitute a major source of superoxide anion (·O2
−) in hypertension. Several studies suggest an important role
of NADPH oxidases in diﬀerent eﬀects mediated by TGF-β1. In this study we show that chronic administration of P144, a peptide
synthesized from type III TGF-β1 receptor, signiﬁcantly reduced the cardiac NADPH oxidase expression and activity as well as
in the nitrotyrosine levels observed in control spontaneously hypertensive rats (V-SHR) to levels similar to control normotensive
WistarKyotorats.Inaddition,P144wasalsoabletoreducethesigniﬁcantincreasesintheexpressionofcollagentypeIproteinand
mRNA observed in hearts from V-SHR. In addition, positive correlations between collagen expression, NADPH oxidase activity,
and nitrotyrosine levels were found in all animals. Finally, TGF-β 1-stimulated Rat-2 exhibited signiﬁcant increases in NADPH
oxidase activity that was inhibited in the presence of P144. It could be concluded that the blockade of TGF-β 1 with P144 inhibited
cardiac NADPH oxidase in SHR, thus adding new data to elucidate the involvement of this enzyme in the proﬁbrotic actions of
TGF-β 1.
1.Introduction
Hypertension is associated with multiple functional and
structural cardiovascular alterations [1, 2]. Among oth-
ers, these alterations are characterized by the progressive
accumulation of ﬁbrillar collagen, namely, collagen type I,
in the myocardium of animals and humans with arterial
hypertension and left ventricular hypertrophy [3]. Although
the exact mechanism by which physiological collagen turns
into pathological ﬁbrotic tissue is still unknown, there are
many studies that suggest an important role of the local
production of the transforming growth factor β 1( T G F - β 1)
[4]. TGF-β 1 acts as a key ﬁbrogenic cytokine in many tissues
by enhancing extracellular matrix synthesis [5].
Currently, in vitro studies have described that the acti-
vation of the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase system has a role in TGF-β 1-induced
eﬀects [6–9]. Moreover, the association of the NADPH oxi-
dasewithTGF-β 1-inducedﬁbrosishasbeenalsoobservedin
several experimental models [10–13]. The NADPH oxidase
has been shown as a major source of superoxide anion
(·O2
−)[ 14]. It consists of a membrane bound cytochrome
formed by a small subunit (p22phox) and a big (NOX1-5,
Duox1-2) subunit, and in some cases, cytoplasmic subunits
that upon phosphorylation bind to the cytochrome [15].
In the heart of rats, Nox2 and Nox4 NADPH isoforms are
expressed. There is evidence that the Nox2-dependent form
of the enzyme is inducible and generates ·O2
−, especially by
humoral activation [15, 16]. The Nox4-dependent enzyme
seems to be constitutively active and may directly generate
hydrogen peroxide (H2O2)[ 17, 18].
It has been described that the synthetic peptide P144,
encompassing amino acids 730–743 from the human
membrane-proximal ligand-binding domain of TGF-β 12 Oxidative Medicine and Cellular Longevity
type III receptor, also called betaglycan, acts as a competitor
of TGF-β 1 type III receptor, sequestering TGF-β 1. P144
is able to inhibit ﬁbrosis in a rat model of hepatic failure
as well as in a murine model of sclerodermia [19, 20].
Furthermore,ourgrouphasrecentlydemonstratedthatP144
prevents myocardial ﬁbrosis and collagen type I synthesis in
experimental hypertension [21].
The possible interrelationship between TGF-β 1 and the
NADPH oxidase in cardiac damage has not yet been studied
in an experimental model of hypertension. Given that TGF-
β 1 is a major contributor to the development of structural
alterations in target organs of hypertension [22], we inves-
tigated whether the chronic treatment with P144 inhibits
cardiac NADPH oxidase and whether this eﬀect is associated
with the cardiac antiﬁbrotic properties of the peptide.
2.MaterialandMethods
2.1. Animals. The study was in agreement with the Guide
for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication no.
85–23, revised 1996) [23], and was approved by the Ethical
Committee for Animal Experimentation of the University of
Navarra (090/05; 100/07). Rats were provided by Harlan UK
Limited(Bicester,UK).Ten-week-oldmaleWistar-kyotorats
(WKY) (n = 10, V-WKY) and 10-week-old male sponta-
neously hypertensive rats (SHR) (n = 10, V-SHR) received
vehicle (saline solution) intraperitoneally for 12 weeks, and
then were sacriﬁced at the age of 22 weeks. In addition, 10-
week-old WKY (n = 10, P144-WKY) and 10-week-old SHR
(n = 10, P144-SHR) were treated with intraperitoneal P144
for 12 weeks and then sacriﬁced. The peptide was dissolved
in saline solution, and the concentration was adjusted for
the body weight to obtain an average daily dose of 1mg/kg
body weight/day. This dose was selected because it had
been demonstrated previously in rodents that P144 exhibits
hepatic and cutaneous antiﬁbrotic activity at doses above
0.5mg/kg body weight/day [15, 16] .A l lr a t sw e r eh o u s e di n
individualcageswithfreeaccesstostandardratchowandtap
water in a quiet room with constant temperature (20–22◦C)
and humidity (50–60%). Before they were sacriﬁced by
decapitation, the rats were weighed and anaesthetized with
Ketamine 75mg/kg (Imalgene 1000, Merial) and Xylazine
5mg/kg (Rompun, Bayer).
2.2. Measurement of Blood Pressure. Systolic blood pressure
(SBP) and diastolic blood pressure (DBP) were measured
in all rats every 2 weeks by the standard tail-cuﬀ method
usinganLE5007PressureComputer(LeticaScientiﬁcInstru-
ments).
2.3.PreparationofTissueSamples. Aftersacriﬁce,heartswere
carefully excised and frozen at −80◦C for mRNA, enzymatic
activity, and protein analysis.
For NADPH oxidase activity and Western blot studies,
hearts were homogenated on ice in phosphate buﬀer saline
(50mM K2HPO4,5 0 m MK H 2PO4, 0.001mM EDTA, and
proteases inhibitor pH = 7) with a glass/glass motor-
driven tissue homogenizer for 2 minutes. The homogenate
was centrifuged at 2000g for 10 minutes. The pellet was
discarded, and the supernatant was stored at −80◦C. Protein
concentration was determined by the Lowry methodology.
2.4. NADPH Oxidase Activity. Chemiluminescence assays
with 10μmol/L lucigenin and 200μmol/L NADPH were
used to measure ·O2
− production in 200μgo ft i s s u e
homogenate. Luminescence was recorded during 10 minutes
in a tube luminometer (Berthold Detection System, Sirius).
Ab u ﬀer blank was subtracted from each reading, and the
value of the area under the curve was used to quantify
chemiluminescence. Data are expressed as relative light units
(RLUs) produced per second per mg of protein.
2.5. Western Blot. To analyze the nitrotyrosine (NT) levels
and the expression of collagen type I and Nox4 and
Nox2 NADPH oxidase isoforms, proteins were separated
by electrophoresis. Membranes were incubated with speciﬁc
antibodies against Nox4 and Nox2 isoforms (Santa Cruz
Biotechnology, INC Santa Cruz), NT (Upstate Biotechnol-
ogy, Millipore), and collagen type I (Biogenesis) overnight
at 4◦C at a dilution of 1:1000. The membranes were incu-
bated with appropiated peroxidase-conjugated secondary
antibodies (GE Healthcare) for 1 hour at room temperature
(1:25000 anti-rabbit for Nox4, 1:10000 anti-mouse for
Nox2, 1:10000 anti-mouse for collagen type I, and 1:20000
anti-mouse for NT). Protein expression was visualized with
the ECL-Advanced chemiluminescence system (Amersham
Biosciences). Bands were analyzed using the Chemidoc
Detection System and the Quantity One software (Bio-Rad)
obtaining densitometric arbitrary units (AU). The blots were
reprobed with a monoclonal α-tubulin antibody (Santa Cruz
Biotechnology, INC Santa Cruz) as a control for loading.
Data are expressed as the relative expression to α-tubulin.
2.6. Real-Time RT-PCR. T h em e s s e n g e rR N A( m R N A )w a s
isolated from total RNA with the Oligotex mRNA KIT
(Quiagen). A real-time PCR reaction was performed using
TaqMan Gene Expression probes: Nox4 (Rn 00585380),
Nox2 (Rn 00576710), p22phox (Rn 00577357), p47phox
(Rn 00586945), TGF-β 1 (Rn 00572010), ﬁbronectin (Rn
00569575), type I collagen (Rn01463848), biglycan (Rn
01529736), connective tissue growth factor (CTGF, Rn
00573960), lysyl oxidase (LOX, Rn 01491829), and 18S
ribosomal RNA(Hs 03003631). Data were normalized to 18S
ribosomal RNA expression. Relative expression of mRNA
was determined by the 2−ΔΔCT method [24].
2.7.CellCulturesandInVitroExperiments. TheRat-2ﬁbrob-
last cell line was purchased from American Type Culture
Collection and maintained in Dulbecco’s modiﬁed Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Invitrogen), Penicilin-Streptomicin solution
(Invitrogen), and Fungizone (Invitrogen). Rat-2 cells were
seeded at a density of 5.25 × 105 cells in T-25 tissue
culture ﬂasks (Nunc) and allowed to adhere overnight. CellsOxidative Medicine and Cellular Longevity 3
were then incubated in reduced-serum medium (1% FBS)
for 24h prior to TGF-β 1 stimulation. Four conditions
were used: (i) cells incubated in reduced serum media, (ii)
cells incubated in reduced serum media containing TGF-
β 1 (10ng/mL), (iii) cells incubated in reduced serum
media containing P144 (200μg/mL), and (iv) cells incubated
in reduced serum media containing TGF-β 1( 1 0 n g / m L )
and P144 (200μg/mL), for 24h prior to harvesting. After
treatment,cellsweretrypsinizedandpelleted.Thecellpellets
were washed in phosphate-buﬀered solution (Invitrogen)
and centrifuged at 1100g for 5min at 4◦C and then used for
protein extraction.
NADPH oxidase activity was performed as above. In this
case, ·O2
− production was measured on 10μg of cell protein.
2.8. Statistical Analysis. Results are given as mean ± SEM.
To analyze the diﬀerences among the four groups, a one-
way ANOVA followed by a Scheﬀe’s test was performed once
normality had been proven (Shapiro-Wilks test); otherwise,
a nonparametric test (Kruskall-Wallis) followed by a Mann-
Whitney U-test (adjusting the alpha-level by Bonferroni
inequality) was used. Bivariate associations were performed
by Pearson’s correlation test. The statistical analysis was
carried out using the computer program SPSS for Windows
version 15.0.
3. Results
3.1. Eﬀects of P144 on Blood Pressure. Values of SBP and
DBP were elevated in V-SHR (SBP: 246.7 ± 3.6mmHg; DBP:
208.6 ± 5.9mmHg) at the age of 22 weeks compared with
V-WKY (SBP: 175.0 ± 3.5mmHg; DBP: 128.7 ± 7.1mmHg;
P<0.01).Interestingly,attheageof22weeks,bloodpressure
values were lower (P<0.01) in P144-SHR (SBP: 215.6
± 5.9mmHg; DBP: 191.9 ± 4.5mmHg) than in V-SHR,
although they were still higher (P<0.01) than in V-WKY.
NosigniﬁcantdiﬀerenceswereobservedbetweenP144-WKY
(SBP: 160.8 ± 5.2mmHg; DBP: 126.9 ± 4.3mmHg) and V-
WKY.
3.2. Eﬀects of P144 on Cardiac NADPH Oxidase. Cardiac
NADPH oxidase activity was higher (P<0.05) in V-SHR
than in V-WKY (Figure 1). The administration of P144
reduced (P<0.05) NADPH oxidase activity in P144-SHR to
the V-WKY levels. No diﬀerences were found between P144-
WKY and V-WKY (Figure 1). Accordingly, cardiac mRNA
and protein levels of Nox2 (Figure 2)w e r eh i g h e r( P<
0.05) in V-SHR than in V-WKY. Compared with V-SHR, the
administration of P144 reduced mRNA and protein levels of
Nox2 (Figure 2) in P144-SHR (P<0.01) to levels similar
to V-WKY. Other NADPH oxidase subunits associated with
Nox2 NADPH oxidase isoform were also evaluated at mRNA
level. Cardiac abundance of p22phox and p47phox was
higher (P<0.01) in V-SHR (2.26 ± 0.15AU and 2.23 ±
0.21AU, respectively) than in V-WKY (1.00 ± 0.09AU for
p22phox and 1.00 ± 0.08AU for p47phox). In the same line
as the NADPH oxidase activity results, the administration of
P144 reduced (P<0.01) the mRNA expression of p22phox
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Figure 1: Eﬀect of P144 on cardiac NADPH oxidase activity. Car-
diac NADPH oxidase-dependent ·O2
− production was determined
by chemiluminescence in the presence of NADPH 200μmol/L,
and it is expressed as relative light units per second (RLU/s).
Histogram represents mean ± SEM (n = 10). V-WKY means
vehicle-treated normotensive rat; P144-WKY, P144-treated WKY
rat; V-SHR, vehicle-treated spontaneously hypertensive rat, P144-
SHR, P144-treated SHR. ∗P<0.05 versus the other groups.
and p47phox on P144-SHR group (1.47 ± 0.1AU and 0.99 ±
0.23AU, respectively) to levels similar to V-WKY.
Interestingly, cardiac mRNA and protein levels of Nox4
NADPH oxidase isoform (Figure 3)w e r eh i g h e r( P<
0.05) in V-SHR than in V-WKY. Compared with V-SHR,
the administration of P144 reduced expression of Nox4
(Figure 3) in P144-SHR (P<0.01) to levels similar to V-
WKY.
3.3. Eﬀects of P144 on Cardiac Levels of Nitrotyrosine. Since
nitrosylation of proteins is considered a consequence of
oxidative stress, the levels of nitrotyrosilated proteins were
quantiﬁed by Western blot. Following the same pattern
that the NADPH oxidase activity determined in heart
homogenates, the NT levels were higher (P<0.05) in the
V-SHR group than in V-WKY (Figure 4(a)). Similarly, the
administration of P144 reduced (P<0.05) the levels of
NT expression in P144-SHR. The levels of nitrotyrosilated
proteins were similar between V-WKY and P144-SHR.
A direct correlation was found between the cardiac
NADPH oxidase activity and NT levels in all the rats (r =
0.407, P<0.01), suggesting that the NADPH oxidase
overactivity may play an important role in the development
of cardiac oxidative stress in this model of hypertension
(Figure 4(b)).
3.4. Eﬀects of P144 on Cardiac Collagen Metabolism. Cardiac
collagen type I protein expression and mRNA levels were
higher (P<0.05) in V-SHR than in V-WKY (Figure 5).
The administration of P144 reduced cardiac collagen type I
protein expression in P144-SHR. No diﬀerences were found
between P144-WKY and V-WKY (Figure 5).
The mRNA expression of TGF-β 1, CTGF, ﬁbronectin,
biglycan and LOX was higher (P<0.01) in V-SHR than in
V-WKY. The chronic administration of P144 resulted in a
decreased expression (P<0.05) of the mRNA levels of these
molecules (Figure 6).4 Oxidative Medicine and Cellular Longevity
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Figure 2: Eﬀect of P144 on cardiac Nox2 subunit expression. (a) mRNA levels of Nox2 expressed as a ratio of gene to 18S values from rat
heart. (b) Expression of the Nox2 protein levels relative to α-tubulin in the rat heart. Representative western blot of the four groups of rats
are shown at the upper part. Histograms represent mean ± SEM (n = 10). V-WKY means vehicle-treated normotensive rat; P144-WKY,
P144-treated WKY rat; V-SHR, vehicle-treated spontaneously hypertensive rat; P144-SHR, P144-treated SHR. ∗P<0.05 versus the other
groups.
N
o
x
4
 
m
R
N
A
 
l
e
v
e
l
s
 
(
n
-
f
o
l
d
)
0
1
2
3
4
5
6
∗∗
V-WKY P144-WKY V-SHR P144-SHR
(a)
0
0.5
1
1.5
2
2.5
N
o
x
4
 
p
r
o
t
e
i
n
 
l
e
v
e
l
s
 
(
n
-
f
o
l
d
)
-
-
Nox4
α-tubulin
∗∗
V-WKY P144-WKY V-SHR P144-SHR
(b)
Figure 3: Eﬀect of P144 on cardiac Nox4 subunit expression. (a) mRNA levels of Nox4 expressed as a ratio of gene to 18S values from
rat heart. (b) Expression of Nox4 protein levels relative to α-tubulin in the rat heart. Representative western blot of the four groups of rats
is shown at the upper part. Histograms represent mean ± SEM (n = 10). V-WKY means vehicle-treated normotensive rat; P144-WKY,
P144-treated WKY rat; V-SHR, vehicle-treated spontaneously hypertensive rat; P144-SHR, P144-treated SHR. ∗∗P<0.01 versus the other
groups.
Moreover, combining data from all groups, direct posi-
tive correlations were found between collagen type I protein
expression and parameters assessing oxidative stress, that is,
NT levels (r = 0.384, P<0.01) and NADPH oxidase activity
(r = 0.372, P<0.05).
3.5. In Vitro Findings. In vitro studies showed that TGF-β
1s t i m u l a t e d( P<0.05) the NADPH oxidase activity in
Rat-2 ﬁbroblasts (Figure 7). Interestingly, P144 completely
prevented the TGF-β1-induced NADPH oxidase activity
(Figure 7).Oxidative Medicine and Cellular Longevity 5
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Figure 4: Eﬀect of P144 on cardiac levels of nitrotyrosine (NT). (a) Levels of NT relative to α-tubulin in the rat heart. Representative western
blot of the four groups of rats are shown at the upper part. Histogram represents mean ± SEM (n = 10). (b) Positive correlation of cardiac
NADPH oxidase activity and levels of NT in all the rats (r = 0.407; P = 0.001; y = 0.0004x +0 .3797). RLU/s means relative light units
per second. V-WKY means vehicle-treated normotensive rat; P144-WKY, P144-treated WKY rat; V-SHR, vehicle-treated spontaneously
hypertensive rat; P144-SHR, P144-treated SHR. ∗P<0.05 versus the other groups.
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Figure 5: Eﬀect of P144 on cardiac collagen type I expression. (a) mRNA levels of collagen type I expressed as a ratio of gene to 18S values
from rat heart. (b) Expression of the collagen type I protein relative to α-tubulin in the rat heart. Representative western blot of the four
groups of rats are shown at the upper part. Histograms represent mean ± SEM (n = 10). V-WKY means vehicle-treated normotensive rat;
P144-WKY, P144-treated WKY rat; V-SHR, vehicle-treated spontaneously hypertensive rat; P144-SHR, P144-treated SHR. ∗P<0.05 and
∗P<0.05 versus the other groups.
4. Discussion
The main ﬁndings of this study are as follows: (i) the chronic
administration of P144 inhibits NADPH oxidase activity and
expression,aswellasNT-assessedoxidativestressintheheart
of SHR; (ii) the chronic administration of P144 prevents the
excessive expression of cardiac collagen type I and molecules
related to collagen synthesis in the same rats; (iii) P144 is
able to block the TGF-β 1-induced NADPH oxidase activity
in cultured rat ﬁbroblasts. Collectively, these ﬁndings suggest6 Oxidative Medicine and Cellular Longevity
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Figure 6: Cardiac mRNA levels of genes assessing collagen
metabolism. Cardiac mRNA expression of TGF-β 1, connective
tissuegrowthfactor(CTGF),ﬁbronectin,biglycan,andlysyloxidase
(LOX) as a ratio of gene to 18S values. Histogram represents mean
± SEM (n = 10). V-WKY means vehicle-treated normotensive
rat; P144-WKY, P144-treated WKY rat; V-SHR, vehicle-treated
spontaneously hypertensive rat; P144-SHR, P144-treated SHR.
∗P<0.05 and ∗∗P<0.01 versus V-WKY; †P<0.05 and ††P<0.01
versus V-SHR.
that interference with the TGF-β 1-NADPH oxidase axis by
P144 may contribute to the cardiac antiﬁbrotic action of this
peptide.
Accumulating evidence indicates that NADPH oxidase
activity is increased in several animal models of heart disease
[25, 26]. In our study, increased NADPH oxidase activity
in V-SHR associated with upregulated Nox2 and associated
subunits, namely, p22phox and p47phox. In addition, the
elevation of cardiac NT levels in untreated V-SHR was
associated with a parallel increase in NADPH oxidase
activity, indicating an increase in oxidative stress in the
heart of V-SHR, presumably by NADPH oxidase activation.
Interestingly, an increased expression of Nox4 isoform was
also observed in the heart of V-SHR. Given that it has been
demonstrated that Nox4 NADPH oxidase isoform generates
mainly H2O2 [17], we can speculate that increased cardiac
NADPH oxidase activity on V-SHR was due to upregulation
of Nox2 isoform and its cytosolic components.
The TGF-β 1 type III receptor or betaglycan is the most
abundant TGF-β 1 binding protein at the cell surface [27].
Betaglycan potentiates TGF-β 1 binding to the signaling type
I and type II receptors and, therefore, may be involved in
ligand presentation [28]. Most of the research to prevent
ﬁbrosis in hypertensive heart disease has been focused on
the eﬀectiveness of drugs interfering with the angiotensin
II-aldosterone-TGF-β 1a x i s[ 29, 30]. In this context, our
group has developed a synthetic peptide from the sequence
of the extracellular region of human betaglycan, the P144,
which was predicted as a potential binder to TGF-β 1b y
ac o m p u t e rp r o g r a m[ 31]. We have recently demonstrated
that P144 prevents myocardial ﬁbrosis and collagen type I
synthesis in SHR [21].
Diverse experimental approaches have suggested a key
role of TGF-β 1 in the activation of the NADPH oxidase. A
study in apolipoprotein E-deﬁcient mice demonstrated that
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Figure 7: Eﬀect of P144 on TGF-β-1-induced NADPH oxidase
activity in Rat-2 ﬁbroblasts. Cells were incubated with 10ng/mL
TGF-β 1(T GF -β 1),200μg/mLP144(P144),andTGF-β 1andP144
(TGF-β 1+P144). Data are expressed as fold increase versus control
cells incubated in the absence of TGF-β 1 and P144 (Control).
Histogram represents mean ± SEM (n = 10). ∗P<0.05 versus the
other groups.
elevated systemic TGF-β 1 levels cause vascular alterations
through the NADPH oxidase activation [32]. In addition,
the treatment with benidipine of Dahl salt-sensitive rats
with heart failure prevented the cardiac dysfunction and
remodeling, which was associated with the suppression of
TGF-β 1 and inhibited the expression of NADPH oxidase
subunits [33]. In rat ventricular myocytes, the oxidative
stress caused by the NADPH oxidase system mediated the
cardiomyocyte contractile dysfunction caused by TGF-β 1
[34]. In agreement with these studies, we have observed
that the treatment with P144 prevented the NADPH oxidase
overactivity observed in SHR. In addition, our data showed
that the reduction of NADPH oxidase activity by chronic
treatment with P144 was associated with a signiﬁcant
reduction of the NADPH oxidase subunit abundance and
diminished NT levels in the heart of P144-SHR. Thus,
P144 treatment appears to limit oxidative stress by lowering
NADPH oxidase abundance in the SHR heart to the levels
of the control strain. Studies in adult rat cardiac ﬁbroblasts
have shown that NADPH oxidase inhibition blocked the
angiotensin II-stimulated collagen production [4]. Finally,
the generation of reactive oxygen species in response to Rac
has been demonstrated in Rat-2 ﬁbroblasts [35]. Findings
from the current study expanded these data by showing that
P144 inhibits the ability of TGF-β 1 to stimulate NADPH
oxidase activity in the same cell line of rat ﬁbroblasts.
Several studies have shown that a reduction in NADPH
oxidase activation was associated with reversed cardiac
damage in several experimental models [33, 36, 37]. In fact,
Wu et al. demonstrated that the antioxidant properties of
acetylsalicylic acid were closely associated with its protective
eﬀect against angiotensin II-induced cardiac hypertrophy
[26]. In addition, the combination of pioglitazone and
candesartan exerted beneﬁcial eﬀects on cardiac ﬁbrosis by
attenuating the NADPH oxidase activity [37]. The results of
the current study allow us to suggest that the antiﬁbroticOxidative Medicine and Cellular Longevity 7
actions of P144 in experimental hypertension may be asso-
ciated with its ability to block the TGF-β-1-induced NADPH
oxidase activation. Nevertheless, further experiments should
be performed to better address this possibility.
Some limitations of the current study must be recog-
nized.First,thedoseof1mg/kgbodyweight/daywasselected
to study the eﬀects of P144 on NADPH oxidase-mediated
TGF-β 1e ﬀects. It was previously demonstrated that P144
exhibits hepatic and cutaneous antiﬁbrotic activity at doses
above 0.5mg/kg body weight per day in rodents [19]. In fact,
other groups of SHR and WKY rats were previously treated
with P144 at the dose of 0.5mg/kg body weight per day,
and no antiﬁbrotic eﬀect at cardiac level was observed (data
not shown). Second, although we did not determine H2O2
production, it has been proposed that levels of Nox4 protein
expression may be representative of Nox4-dependent H2O2
production. Finally, to better understand the link between
NADPH oxidase and collagen production, further data from
in vitro studies would be necessary.
In conclusion, the present results support that P144,
a peptide synthesized from type III TGF-β 1r e c e p t o r ,
prevented NADPH oxidase-dependent oxidative stress and
ﬁbrosis in hearts of SHR. Thus, P144 may be interesting as
a therapeutic agent for the protection of the heart against
oxidative stress and ﬁbrosis in hypertension. Further studies
should be performed to better address this possibility.
Abbreviations
NADPH: Nicotinamide adenine dinucleotide
phosphate
TGF-β 1: Transforming growth factor-β 1
·O2
−: Superoxide anion
SHR: Spontaneously hypertensive rats
NT: Nitrotyrosine
CTGF: Connective tissue growth factor
LOX: Lysyl oxidase
SBP: Systolic blood pressure
DBP: Diastolic blood pressure.
Acknowledgments
This paper was funded through the agreement between the
Foundation for Applied Medical Research (FIMA) and UTE
project CIMA, the Department of Education of Government
of Navarra (87/2007), the Ministry of Science and Innova-
tion (RECAVA RD06/0014/0008) (SAF2008-04228), and the
European Union (MEDIA project grant HEALTH-F2-2010-
261409). The authors thank Ana Montoya, Raquel Ros, Idoia
Rodr´ ıguez, and the Morphology and Imaging Department
for their technical support.
References
[1] M. J. Brown and S. Haydock, “Pathoaetiology, epidemiology
and diagnosis of hypertension,” Drugs, vol. 59, no. 2, pp. 1–12,
2000.
[2] G. A. Mensah, J. B. Croft, and W. H. Giles, “The heart, kidney,
and brain as target organs in hypertension,” Current Problems
in Cardiology, vol. 28, pp. 156–193, 2003.
[3] J.D´ ıez, A.Gonz´ alez, B.L´ opez,andR.Querejeta,“Mechanisms
of disease: pathologic structural remodeling is more than
adaptive hypertrophy in hypertensive heart disease,” Nature
Clinical Practice Cardiovascular Medicine,v o l .2 ,n o .4 ,p p .
209–216, 2005.
[4] P. J. Lijnen, V. V. Petrov, and R. H. Fagard, “Induction of
cardiac ﬁbrosis by transforming growth factor-β1,” Molecular
Genetics and Metabolism, vol. 71, no. 1-2, pp. 418–435, 2000.
[5] W. A. Border and N. A. Noble, “Transforming growth factor β
in tissue ﬁbrosis,” New England Journal of Medicine, vol. 331,
no. 19, pp. 1286–1292, 1994.
[ 6 ]E .M a t a - G r e e n w o o d ,A .G r o b e ,S .K u m a r ,Y .N o s k i n a ,a n d
S. M. Black, “Cyclic stretch increases VEGF expression in
pulmonary arterial smooth muscle cells via TGF-β1 and reac-
tive oxygen species: as requirement for NAD(P)H oxidase,”
American Journal of Physiology, vol. 289, no. 2, pp. L288–L298,
2005.
[7] I. Cucoranu, R. Clempus, A. Dikalova et al., “NAD(P)H
oxidase 4 mediates transforming growth factor-β1-induced
diﬀerentiation of cardiac ﬁbroblasts into myoﬁbroblasts,”
Circulation Research, vol. 97, no. 9, pp. 900–907, 2005.
[8] M. M. Murillo, I. Carmona-Cuenca, G. Del Castillo et
al., “Activation of NADPH oxidase by transforming growth
factor-β in hepatocytes mediates up-regulation of epidermal
growth factor receptor ligands through a nuclear factor-κB-
dependent mechanism,” Biochemical Journal, vol. 405, no. 2,
pp. 251–259, 2007.
[9] V. J. Thannickal and B. L. Fanburg, “Activation of an H2O2-
generating NADH oxidase in human lung ﬁbroblasts by trans-
forminggrowthfactorβ1,”JournalofBiologicalChemistry,vol.
270, no. 51, pp. 30334–30338, 1995.
[10] Y. Ishikawa, T. Nishikimi, K. Akimoto, K. Ishimura, H. Ono,
and H. Matsuoka, “Long-term administration of Rho-kinase
inhibitor ameliorates renal damage in malignant hypertensive
rats,” Hypertension, vol. 47, no. 6, pp. 1075–1083, 2006.
[11] X. P. Liu, Y. J. Pang, W. W. Zhu et al., “Benazepril,
an angiotensin-converting enzyme inhibitor, alleviates renal
injury in spontaneously hypertensive rats by inhibiting
advanced glycation end-product-mediated pathways,” Clinical
and Experimental Pharmacology and Physiology, vol. 36, no. 3,
pp. 287–296, 2009.
[12] T. Namikoshi, N. Tomita, M. Satoh et al., “Olmesartan
ameliorates renovascular injury and oxidative stress in zucker
obese rats enhanced by dietary protein,” American Journal of
Hypertension, vol. 20, no. 10, pp. 1085–1091, 2007.
[ 1 3 ]S .O h t o m o ,M .N a n g a k u ,Y .I z u h a r a ,S .T a k i z a w a ,C .V .Y .D .
Strihou, and T. Miyata, “Cobalt ameliorates renal injury in
an obese, hypertensive type 2 diabetes rat model,” Nephrology
Dialysis Transplantation, vol. 23, no. 4, pp. 1166–1172, 2008.
[14] A. M. Briones and R. M. Touyz, “Oxidative stress and hyper-
tension: current concepts,” Current Hypertension Reports, vol.
12, no. 2, pp. 135–142, 2010.
[15] K. Bedard and K. H. Krause, “The NOX family of ROS-
generating NADPH oxidases: physiology and pathophysiol-
ogy,” Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007.
[16] A. Nabeebaccus, M. Zhang, and A. M. Shah, “NADPH
oxidases and cardiac remodelling,” Heart Failure Reviews, vol.
16, no. 1, pp. 5–12, 2011.
[ 1 7 ]K .D .M a r t y n ,L .M .F r e d e r i c k ,K .V o nL o e h n e y s e n ,M .C .
Dinauer, and U. G. Knaus, “Functional analysis of Nox4
reveals unique characteristics compared to other NADPH
oxidases,” Cellular Signalling, vol. 18, no. 1, pp. 69–82, 2006.
[18] S. I. Dikalov, A. E. Dikalova, A. T. Bikineyeva, H. H. H. W.
Schmidt, D. G. Harrison, and K. K. Griendling, “Distinct roles8 Oxidative Medicine and Cellular Longevity
of Nox1 and Nox4 in basal and angiotensin II-stimulated
superoxide and hydrogen peroxide production,” Free Radical
Biology and Medicine, vol. 45, no. 9, pp. 1340–1351, 2008.
[19] B. Santiago, I. Guti´ errez-Ca˜ nas, J. Dotor et al., “Topical appli-
cation of a peptide inhibitor of transforming growth factor-
β1 ameliorates bleomycin-induced skin ﬁbrosis,” Journal of
Investigative Dermatology, vol. 125, no. 3, pp. 450–455, 2005.
[ 2 0 ]I .J .E z q u e r r o ,J .J .L a s a r t e ,J .D o t o re ta l . ,“ As y n t h e t i cp e p t i d e
from transforming growth factor β type III receptor inhibits
liverﬁbrogenesisinratswithcarbontetrachlorideliverinjury,”
Cytokine, vol. 22, no. 1-2, pp. 12–20, 2003.
[21] N. Hermida, B. L´ opez, A. Gonz´ alez et al., “A synthetic
peptide from transforming growth factor-β1 type III receptor
prevents myocardial ﬁbrosis in spontaneously hypertensive
rats,” Cardiovascular Research, vol. 81, no. 3, pp. 601–609,
2009.
[22] J. Dabek, A. Kułach, B. Monastyrska-Cup, and Z. Gasior,
“Transforming growth factor β and cardiovascular diseases:
the other facet of the “protective cytokine”,” Pharmacological
Reports, vol. 58, no. 6, pp. 799–805, 2006.
[23] US National Institutes of Health, G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals, NIH Publication no. 85-23, Washington,
DC, USA, 1996.
[24] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene
expression data using real-time quantitative PCR and the 2-
ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
[25] M. C. Wendt, A. Daiber, A. L. Kleschyov et al., “Diﬀerential
eﬀects of diabetes on the expression of the gp91 phox homo-
logues nox1 and nox4,” Free Radical Biology and Medicine, vol.
39, no. 3, pp. 381–391, 2005.
[26] R. Wu, M. A. Laplante, and J. De Champlain, “Prevention
of angiotensin II-induced hypertension, cardiovascular hyper-
trophy and oxidative stress by acetylsalicylic acid in rats,”
Journal of Hypertension, vol. 22, no. 4, pp. 793–801, 2004.
[27] J. Massagu´ e and B. Like, “Cellular receptors for type β
transforming growth factor. Ligand binding and aﬃnity
labeling in human and rodent cell lines,” Journal of Biological
Chemistry, vol. 260, no. 5, pp. 2636–2645, 1985.
[28] F. L´ opez-Casillas, J. L. Wrana, and J. Massagu´ e, “Betaglycan
presents ligand to the TGFβ signaling receptor,” Cell, vol. 73,
no. 7, pp. 1435–1444, 1993.
[29] W. Arozal, K. Watanabe, P. T. Veeraveedu et al., “Eﬀects of
angiotensin receptor blocker on oxidative stress and cardio-
renalfunctioninstreptozotocin-induceddiabeticrats,”Biolog-
ical and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1411–1416,
2009.
[30] K. Nagata, F. Somura, K. Obata et al., “AT1 receptor blockade
reduces cardiac calcineurin activity in hypertensive rats,”
Hypertension, vol. 40, no. 2, pp. 168–174, 2002.
[31] J. Esparza-L´ o p e z ,J .L .M o n t i e l ,M .M .V i l c h i s - L a n d e r o s ,
T. Okadome, K. Miyazono, and F. L´ opez-Casillas, “Ligand
binding and functional properties of betaglycan, a co-receptor
of the transforming growth factor-β superfamily. Specialized
binding regions for transforming growth factor-β and inhibin
A,” Journal of Biological Chemistry, vol. 276, no. 18, pp. 14588–
14596, 2001.
[32] A. Buday, P. Orsy, M. God´ o et al., “Elevated systemic TGF-
β impairs aortic vasomotor function through activation of
NADPH oxidase-driven superoxide production and leads to
hypertension, myocardial remodeling, and increased plaque
f o r m a t i o ni na p o E- / -m i c e , ”American Journal of Physiology,
vol. 299, no. 2, pp. H386–H395, 2010.
[33] T. Ohno, N. Kobayashi, K. Yoshida, H. Fukushima, and H.
Matsuoka, “Cardioprotective eﬀect of benidipine on cardiac
performance and remodeling in failing rat hearts,” American
Journal of Hypertension, vol. 21, no. 2, pp. 224–230, 2008.
[34] S. Li, X. Li, H. Zheng, B. Xie, K. R. Bidasee, and G. J. Rozan-
ski, “Pro-oxidant eﬀect of transforming growth factor-β1
mediates contractile dysfunction in rat ventricular myocytes,”
Cardiovascular Research, vol. 77, no. 1, pp. 107–117, 2008.
[35] C. H. Woo, Z. W. Lee, B. C. Kim, K. S. Ha, and J. H.
Kim, “Involvement of cytosolic phospholipase A2, and the
subsequent release of arachidonic acid, in signallingby Racfor
the generation of intracellular reactive oxygen species in Rat-2
ﬁbroblasts,” Biochemical Journal, vol. 348, no. 3, pp. 525–530,
2000.
[36] I. Papparella, G. Ceolotto, L. Berto et al., “Vitamin C
prevents zidovudine-induced NAD(P)H oxidase activation
and hypertension in the rat,” Cardiovascular Research, vol. 73,
no. 2, pp. 432–438, 2007.
[37] T. Nakamura, E. Yamamoto, K. Kataoka et al., “Beneﬁcial
eﬀects of pioglitazone on hypertensive cardiovascular injury
are enhanced by combination with candesartan,” Hyperten-
sion, vol. 51, no. 2, pp. 296–301, 2008.